Cellular and Molecular Gastroenterology and Hepatology (Jan 2023)
Hepatitis B Virus Targets Lipid Transport Pathways to Infect HepatocytesSummary
- Knud Esser,
- Xiaoming Cheng,
- Jochen M. Wettengel,
- Julie Lucifora,
- Lea Hansen-Palmus,
- Katharina Austen,
- Armando A. Roca Suarez,
- Sarah Heintz,
- Barbara Testoni,
- Firat Nebioglu,
- Minh Tu Pham,
- Shangqing Yang,
- Alma Zernecke,
- Dirk Wohlleber,
- Marc Ringelhan,
- Mathias Broxtermann,
- Daniel Hartmann,
- Norbert Hüser,
- Julia Mergner,
- Andreas Pichlmair,
- Wolfgang E. Thasler,
- Mathias Heikenwalder,
- Georg Gasteiger,
- Andreas Blutke,
- Axel Walch,
- Percy A. Knolle,
- Ralf Bartenschlager,
- Ulrike Protzer
Affiliations
- Knud Esser
- Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Munich, Germany; Correspondence Address correspondence to: Knud Esser, PhD, and Prof. Ulrike Protzer, MD, Institute of Virology, Technical University of Munich / Helmholtz Munich, Trogerstr. 30, D-81675 Munich, Germany.
- Xiaoming Cheng
- Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Munich, Germany
- Jochen M. Wettengel
- Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Munich, Germany
- Julie Lucifora
- INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon (CRCL), Lyon, and University of Lyon, Université Claude-Bernard (UCBL), Lyon, France; CIRI—Centre International de Recherche en Infectiologie, Inserm, U1111, University of Lyon, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS Lyon, France
- Lea Hansen-Palmus
- Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Munich, Germany
- Katharina Austen
- Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Munich, Germany
- Armando A. Roca Suarez
- CIRI—Centre International de Recherche en Infectiologie, Inserm, U1111, University of Lyon, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS Lyon, France
- Sarah Heintz
- CIRI—Centre International de Recherche en Infectiologie, Inserm, U1111, University of Lyon, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS Lyon, France
- Barbara Testoni
- CIRI—Centre International de Recherche en Infectiologie, Inserm, U1111, University of Lyon, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS Lyon, France
- Firat Nebioglu
- Heidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Diseases Research, Heidelberg, Germany
- Minh Tu Pham
- Heidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Diseases Research, Heidelberg, Germany
- Shangqing Yang
- Heidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Diseases Research, Heidelberg, Germany
- Alma Zernecke
- Institute of Experimental Biomedicine, University Hospital Würzburg, Würzburg, Germany
- Dirk Wohlleber
- Institute of Molecular Immunology and Experimental Oncology, University Hospital rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany; German Center for Infection Research (DZIF), Munich and Heidelberg partner sites, Munich and Heidelberg, Germany
- Marc Ringelhan
- German Center for Infection Research (DZIF), Munich and Heidelberg partner sites, Munich and Heidelberg, Germany; 2nd Medical Department, University Hospital rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany
- Mathias Broxtermann
- Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Munich, Germany
- Daniel Hartmann
- Department of Surgery, University Hospital rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany
- Norbert Hüser
- Department of Surgery, University Hospital rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany
- Julia Mergner
- Bavarian Center for Biomolecular Mass Spectrometry at Klinikum rechts der Isar (BayBioMS@MRI), TUM, Munich, Germany
- Andreas Pichlmair
- Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Munich, Germany; German Center for Infection Research (DZIF), Munich and Heidelberg partner sites, Munich and Heidelberg, Germany; Bavarian Center for Biomolecular Mass Spectrometry at Klinikum rechts der Isar (BayBioMS@MRI), TUM, Munich, Germany
- Wolfgang E. Thasler
- Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, Grosshadern Hospital, Ludwig Maximilians University, Munich, Germany
- Mathias Heikenwalder
- Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Munich, Germany
- Georg Gasteiger
- Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Munich, Germany
- Andreas Blutke
- Institute of Pathology, Helmholtz Zentrum München, Neuherberg, Germany
- Axel Walch
- Institute of Pathology, Helmholtz Zentrum München, Neuherberg, Germany
- Percy A. Knolle
- Institute of Molecular Immunology and Experimental Oncology, University Hospital rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany; German Center for Infection Research (DZIF), Munich and Heidelberg partner sites, Munich and Heidelberg, Germany
- Ralf Bartenschlager
- Heidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Diseases Research, Heidelberg, Germany; German Center for Infection Research (DZIF), Munich and Heidelberg partner sites, Munich and Heidelberg, Germany; Division Virus-Associated Carcinogenesis, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Ulrike Protzer
- Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Munich, Germany; German Center for Infection Research (DZIF), Munich and Heidelberg partner sites, Munich and Heidelberg, Germany; Correspondence Address correspondence to: Knud Esser, PhD, and Prof. Ulrike Protzer, MD, Institute of Virology, Technical University of Munich / Helmholtz Munich, Trogerstr. 30, D-81675 Munich, Germany.
- Journal volume & issue
-
Vol. 16,
no. 2
pp. 201 – 221
Abstract
Background & Aims: A single hepatitis B virus (HBV) particle is sufficient to establish chronic infection of the liver after intravenous injection, suggesting that the virus targets hepatocytes via a highly efficient transport pathway. We therefore investigated whether HBV uses a physiological liver-directed pathway that supports specific host-cell targeting in vivo. Methods: We established the ex vivo perfusion of intact human liver tissue that recapitulates the liver physiology to investigate HBV liver targeting. This model allowed us to investigate virus-host cell interactions in a cellular microenvironment mimicking the in vivo situation. Results: HBV was rapidly sequestered by liver macrophages within 1 hour after a virus pulse perfusion but was detected in hepatocytes only after 16 hours. We found that HBV associates with lipoproteins in serum and within machrophages. Electron and immunofluorescence microscopy corroborated a co-localization in recycling endosomes within peripheral and liver macrophages. Recycling endosomes accumulated HBV and cholesterol, followed by transport of HBV back to the cell surface along the cholesterol efflux pathway. To reach hepatocytes as final target cells, HBV was able to utilize the hepatocyte-directed cholesterol transport machinery of macrophages. Conclusions: Our results propose that by binding to liver targeted lipoproteins and using the reverse cholesterol transport pathway of macrophages, HBV hijacks the physiological lipid transport pathways to the liver to most efficiently reach its target organ. This may involve transinfection of liver macrophages and result in deposition of HBV in the perisinusoidal space from where HBV can bind its receptor on hepatocytes.